OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
Silvia Rota, Daniele Urso, Daniel J. van Wamelen, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 9

Showing 9 citing articles:

Wearable devices may aid the recognition of fluctuation-related pain in Parkinson’s disease—An exploratory, cross-sectional analysis of two prospective observational studies
Katarina Rukavina, Juliet Staunton, Pavlos Zinzalias, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0316563-e0316563
Open Access | Times Cited: 1

Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease
Stuart Isaacson, Peter Jenner
Clinical Parkinsonism & Related Disorders (2025), pp. 100303-100303
Open Access

Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access

Application of single wrist-wearable accelerometry for objective motor diary assessment in fluctuating Parkinson’s disease
Matthias Löhle, Jonathan Timpka, Alexander Bremer, et al.
npj Digital Medicine (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 6

Impact of Physical Exercise on Levodopa Therapy Across Parkinson’s Disease Stages
Monika Figura, Agnieszka Mrozowicz, Łukasz Milanowski, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 5, pp. 1039-1049
Open Access | Times Cited: 1

How and why the adenosine A2A receptor became a target for Parkinson’s disease therapy
Peter Jenner, Tomoyuki Kanda, Akihisa Mori
International review of neurobiology (2023), pp. 73-104
Closed Access | Times Cited: 2

Can Continuous Levodopa Delivery Be Achieved in the Absence of Intrajejunal Levodopa Infusion? Implications for India and Underserved Countries
К. Ray Chaudhuri, Lucia Batzu
Movement Disorders Clinical Practice (2023) Vol. 11, Iss. 1, pp. 21-29
Open Access | Times Cited: 2

Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson’s disease: is it an improvement on other delivery?
Sheila A Doggrell
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 9, pp. 1189-1199
Closed Access | Times Cited: 1

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease
Daniel J. van Wamelen, Valentina Leta, К. Ray Chaudhuri, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 10, pp. 1606-1620
Closed Access

Page 1

Scroll to top